فيشال شاندرا

• Oversee P&L, Business Development (BD) & Strategic initiatives for 4 SBU’s in Germany with turnover of 13.5 Million Euros spread across 40+ countries of Europe, GCC-MENA, CIS, Francophone Africa.
• Enable Out-licensing, CDMO services, Technology Transfer Projects, Packaging, Quality testing, Marketing & Sales strategies of Branded and Generic Pharmaceutical products and medical devices.
• Conduct Market research, analyze current regulatory & Sales trends for enabling Geographical expansion of the portfolio and create High quality presentations for Senior internal and external audiences.
• Data Gathering and Conducting Due diligence, Detailed analysis of Business metrics by incorporating modern analytic tools & strengthen the stakeholder relationships and expectations.
• Provide Strategic direction & Consultancy for Training business development group resulting in faster business lead conversion.
• Communicating organizational vision, liaise with functional team and act as a central point of contact for supply chain, sourcing & Procurement, operations and finance teams in each territory to meet the forecasted business plan.
• Liaising with different government and private agencies in key markets for getting updates on pharmaceutical regulations new product registration approvals and tender related information.

Key Achievements
- Positioned company as one of the largest suppliers of Meropenem in regulated market of Europe; gained approx.45% market share in Germany, 38% in UK, 60%+ in Italy, and 70% and Cyprus.
- Enabled Business strategy for channel partners to win major tenders in public & private market in EMEA region and improve sales.
- Company won an exceptional award of 100% supplying in NHS-UK tenders for Gemcitabine (All 3 regions awarded to Venus) for 2018-2020.
- Developed new business opportunities and acquired clients in Central EU, Baltic & Balkan European regions and UAE, Kuwait, Bahrain, Egypt, Morocco, Lebanon, Jordon, Iraq from MENA geography for Oncology products and Critical care Antibiotics.
- For period 2017-2019: Enabled CAGR of 82% in revenues and raising profits by 8.5%
- Consistently developed new initiatives to finalize agreements and submitted regulatory processes to launch 27 new markets with varied business models leading higher returns.
- Reduced packaging unit operational costs by 6% through cost containment, improved sourcing, and organizational restructuring.

Honored for customer centric focus and engaging solutions to long standing issues.

From just 6 clients in 2017, Organization has 44 clients in 2020 with a broad geographical spread
Felicitated for being 4th among Fortune 100 Employees for the Organization from a team of 1000+ colleagues & Peers across Venus
Group.

• Managed all business aspects of Amoxiclav and Nutraceutical start-up projects.
• Identified external suppliers to finalize revenue channels and products for the new global business unit.
• Sourced and selected vendors and manufacturing associates.
• Connected dossier development plan matching regulatory climate of shortlisted markets.

Key achievements
- Ascertained regulatory requirements and aligned backhand team for audits and dossier filings.
- Established regulatory, distribution, and marketing framework and completed agreements in unrepresented geographical GCC/Russia area.
- Assessed market dynamics of GCC-MENA/Russia markets for various SKUs of Co-Amoxiclav molecule.
- Developed product portfolio for international Nutraceutical business with focus on SE Asian Cluster.
- Created and executed market entry plan by identifying distribution and marketing associates and worked on market specific business prototype to optimize return on investment.

• Managed all business aspects of Amoxiclav and Nutraceutical start-up projects.
• Identified external suppliers to finalize revenue channels and products for the new global business unit.
• Sourced and selected vendors and manufacturing associates.
• Connected dossier development plan matching regulatory climate of shortlisted markets.

Key achievements
- Ascertained regulatory requirements and aligned backhand team for audits and dossier filings.
- Established regulatory, distribution, and marketing framework and completed agreements in unrepresented geographical GCC/Russia area.
- Assessed market dynamics of GCC-MENA/Russia markets for various SKUs of Co-Amoxiclav molecule.
- Developed product portfolio for international Nutraceutical business with focus on SE Asian Cluster.
- Created and executed market entry plan by identifying distribution and marketing associates and worked on market specific business prototype to optimize return on investment.

• Supervised 200+ international sales and marketing staff in 8 countries.
• Initiated new OL-contract manufacturing projects and negotiated marketing agreements for pharmaceutical and nutraceutical products in CIS, SE Asia & Latin America.
• Secured licensing contracts to raise revenues and initiated Research and Development /CDMO projects to turn R&D department into a revenue source.
• Secured in-licensing deals & Rolled out long term procurement strategies to strengthen the product portfolio for global business teams.
Key achievements
- Helped initiate company operations and increase annual sales to USD $20M by energizing business procedures and introducing viable business models.
- Aided to reverse underperforming call canter operations business (herbal supplements) and improved revenue by 50%+ through reviewing metrics and updating product development strategies.
- Added 13 new International markets and laid strategic marketing plans.
- Introduced global product portfolio and identified market niche by initiating innovative campaigns, finding new products, and employing new marketing and sales ideas for key emerging markets.
- Played key role in making TuginaTM: Tranexamic Acid Injection a brand leader in CIS-Central Asian Markets and TulizidTM: Ceftazidime Injection, surpassing Fortum TM (GSK) to become No. 1 selling Ceftazidime in Eastern-European Rx segment.
- Aligned back-end teams allowing manufacturing unit(s) to secure PIC/S (EU GMP approval).
- Implemented successful product and scientific communication training initiatives for Eastern European & Middle East clients to promote corporate image and improve revenue.

Guided panel of opinion leaders and professors from renowned medical universities endorsing TuginaTM as premium new generation Hemostatic and persuaded MOH Ukraine to include Tranexamic acid in tender list for government purchase for hospitals. Worked with local distributors and manufacturers aid bulk purchase of Tulip products and help compete for government and hospital business.
•Improved sales by USD $1M (CAGR +72% over 2008-2009) in 2010 despite severe recession and stringent regulatory norms by MOH Ukraine with only 4 products and small field force.
•Launched Tranexamic acid injection TuginaTM for first time in Ukraine pharmaceutical market.
•Established TulizidTM as No.3-rated Ceftazidime in Ukraine in second year after launch despite presence of strong multinational competition and overcrowded antibiotic segment.
•Introduced Aceclofenac; InfenacTM as new generation NSAID for first time in Ukraine.